DarioHealth (NASDAQ:DRIO) Earns Buy Rating from Analysts at Alliance Global Partners

Alliance Global Partners assumed coverage on shares of DarioHealth (NASDAQ:DRIO) in a report released on Wednesday morning, Marketbeat reports. The firm issued a buy rating and a $12.00 price objective on the stock.

A number of other equities research analysts have also recently weighed in on the stock. TD Cowen cut their price objective on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, August 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research note on Friday, July 10th. Finally, Stifel Nicolaus restated a “buy” rating and set a $10.00 price target on shares of DarioHealth in a research report on Thursday, May 14th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, DarioHealth presently has a consensus rating of “Hold” and a consensus price target of $10.00.

DarioHealth Stock Up 4.5%

DRIO opened at $7.49 on Wednesday. DarioHealth has a 12 month low of $5.84 and a 12 month high of $17.74. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.31 and a quick ratio of 1.92. The stock has a market cap of $73.40 million, a P/E ratio of -1.22 and a beta of 1.11. The stock’s 50 day moving average price is $7.09 and its 200 day moving average price is $8.11.

DarioHealth (NASDAQ:DRIO) last announced its earnings results on Tuesday, August 11th. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.37. DarioHealth had a negative return on equity of 54.81% and a negative net margin of 169.87%.The firm had revenue of $5.18 million for the quarter, compared to the consensus estimate of $5.92 million. As a group, research analysts predict that DarioHealth will post -3.12 earnings per share for the current year.

Insider Activity at DarioHealth

In other news, Director Dennis Matheis acquired 14,430 shares of the business’s stock in a transaction dated Thursday, July 23rd. The stock was acquired at an average price of $6.93 per share, for a total transaction of $99,999.90. Following the completion of the acquisition, the director directly owned 43,026 shares in the company, valued at $298,170.18. This represents a 50.46% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in DarioHealth in the 4th quarter valued at about $35,000. BlackRock Inc. acquired a new position in shares of DarioHealth in the 2nd quarter worth approximately $249,000. Geode Capital Management LLC raised its holdings in shares of DarioHealth by 167.9% in the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after purchasing an additional 31,063 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after purchasing an additional 43,513 shares in the last quarter. Finally, Nantahala Capital Management LLC bought a new stake in shares of DarioHealth in the 2nd quarter worth approximately $4,030,561,000. 33.39% of the stock is owned by institutional investors and hedge funds.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.